Growth hormone replacement in adults -current standards and new perspectives

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 29, Issue 1, 2015, Pages 115-123

  Höybye, Charlotte ^a   Christiansen, Jens Sandahl ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Effects of growth hormone treatment; Growth hormone; Growth hormone deficiency in adults; Growth hormone treatment

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE;

ARTHRALGIA; BODY COMPOSITION; CANCER INCIDENCE; CARDIOVASCULAR RISK; CARPAL TUNNEL SYNDROME; DRUG INDUCED HEADACHE; EDEMA; FITNESS; FRACTURE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; JOINT STIFFNESS; MORBIDITY; MORTALITY; MYALGIA; PARESTHESIA; PHYSICAL CAPACITY; PHYSIOLOGY; QUALITY OF LIFE; REVIEW; ADULT; DEFICIENCY; HYPOPITUITARISM; TREATMENT OUTCOME;

ADULT; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; TREATMENT OUTCOME;

EID: 84927937474     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2014.09.006     Document Type: Review

References (53)

1. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998; 19: 717-97.
2. Jørgensen JO, Møller N, Wolthers T, et al. Fuel metabolism in growth hormone-deficient adults. Metabolism 1995; 44 (10 Suppl. 4) : 103-7.
3. Jørgensen JO, Møller L, Krag M, et al. Effects of growth hormone on glucose and fat metabolism in human subjects. Endocrinol Metab Clin North Am 2007; 36 (1) : 75-87.
4. Carroll PV, Christ ER, Bengtsson BA, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998; 83: 382-95.
5. Molitch ME, Clemmons DR, Malozowski S, et al. Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96 (6) : 1587-609.
6. Holly JM, Perks CM. Insulin-like growth factor physiology. What we had learned from human studies. Endocrinol Metab Clin North Am 2012; 41: 249-63.
7. Stochholm K, Gravholt CH, Laursen T, et al. Incidence of GH deficiency - A nationwide study. Eur J Endocrinol 2006; 155: 61-71.
8. Cuneo RC, Salomon F, McGauley GA, et al. The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf) 1992; 37 (5) : 387-97.
9. Holmer H, Svensson J, Rylander L, et al. Psychosocial health and levels of employment in 851 hypopituitary Swedish patients on long-term GH therapy. Psychoneuroendocrinology 2013; 38: 842-52.
10. Gazzaruso C, Gola M, Karamouzis I, et al. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH-an update. J Clin Endocrinol Metab 2014; 99 (1) : 18-29.
11. Abdu TA, Neary R, Elhadd TA, et al. Coronary risk in growth hormone deficient hypopituitary adults: Increased predicted risk is due largely to lipid profile abnormalities. Clin Endocrinol (Oxf) 2001; 55 (2) : 209-16.
12. Appelman-Dijkstra NM, Claessen KMJA, Roelfsema F, et al. Long-term effects of recombinant human GH replacement in adults with GH deficiency: A systematic review. Eur J Endocrinol 2013; 169: R1-14.
13. Deepak D, Daousi C, Javadpour M, et al. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency. Growth Horm IGF Res 2010; 20 (3) : 220-5.
14. Stochholm K, Laursen T, Green A, et al. Morbidity and GH deficiency: A nationwide study. Eur J Endocrinol 2008; 158 (4) : 447-57.
15. Erfurth EM. Update in mortality in GH-treated patients. J Clin Endocrinol Metab 2013; 98: 4219-26.
16. Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 2011: 555-9.
17. Corneli G, Di SC, Baldelli R, et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol 2005; 153: 257-64.
18. Aimaretti G, Corneli G, Razzore P, et al. Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J Clin Endocrinol Metab 1998; 83: 1615-8.
19. Darzy KH, Aimaretti G, Wieringa G, et al. The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J Clin Endocrinol Metab 2003; 88: 95-102.
20. Raben MS. Human Growth hormone. Recent Prog Horm Res 1959; 15: 71-105.
21. Kastrup KW, Christiansen JS, Andersen JK, et al. Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children. Acta Endocrinol 1983; 104: 148-52.
22. Thorngren KG, Hansson LI. Effect of administration frequency of growth hormone on longitudinal bone growth in the hypophysectiomized rat. Acta Endocrinol 1977; 84: 497-502.
23. Clark RG, Jansson JO, Isaksson O, et al. Intraveneous growth hormone (GH) : Growth responses to patterned infusions in hypophysectiomized rats. J Endocrinol 1985; 104: 53-61.
24. Jørgensen JO, Møller N, Lauritzen T, et al. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: Effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab 1990; 70: 207-14.
25. Höybye C, Rudling M. Long-term growth hormone (GH) treatment to GH-deficient adults; comparison between one and two daily injections. J Endocrinol Invest 2006; 29: 950-6.
26. Laursen T, Gravholt CH, Heickendorff L, et al. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. J Clin Endocrinol Metab 2001; 86: 1222-8.
27. Koltowska-Häggström M, Mattsson AF, Monson JP, et al. Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life. Eur J Endocrinol 2006; 155: 109-19.
28. Kokshoorn NE, Biermasz NR, Roelfsema F, et al. GH replacement therapy in elderly GH-deficient patients: A systematic review. Eur J Endocrinol 2011; 164 (5) : 657-65.
29. Jørgensen AP, Fougner KJ, Ueland T, et al. Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency. Growth Horm IGF Res 2011; 21 (2) : 69-75.
30. Hazem A, Elamin MB, Bancos I, et al. Body composition and quality of life in adults treated with GH therapy: A systematic review and meta-analysis. Eur J Endocrinol 2012; 166 (1) : 13-20.
31. Götherström G, Svensson J, Koranyi J, et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: Sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 2001; 86 (10) : 4657-65.
32. van der Klaauw AA, Romijn JA, Biermasz NR, et al. Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. Eur J Endocrinol 2006; 155 (5) : 701-8.
33. Götherström G, Bengtsson BA, Bosaeus I, et al. 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab 2007; 92 (4) : 1442-5.
34. Elbornsson M, Götherström G, Bosæus I, et al. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol 2013; 168 (5) : 745-53.
35. Janssen YJ, Doornbos J, Rolfsema F. Changes in muscle volume, strength and biogenetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 1999; 84 (1) : 279-84.
36. Ezzat S, Fear S, Gaillard RC, et al. Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults. Erratum appears in Journal of Clinical Endocrinology and Metabolism 2002 10 4461.
37. J Clin Endocrinol Metab 2002; 87: 2725-33.
38. Holmer H, Svensson J, Rylander L, et al. Fracture incidence in GH-deficient patients on complete hormone replacement including GH. J Bone Miner Res 2007; 22: 1842-50.
39. Svensson J, Bengtsson BA, Rosén T, et al. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 2004; 89 (7) : 3306-12.
40. Burman P, Mattsson AF, Johannsson G, et al. Deaths among adult patients with hypopituitarism: Hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J Clin Endocrinol Metab 2013; 98 (4) : 1466-75.
41. Gaillard RC, Mattsson AF, Akerblad AC, et al. Overall and cause and specific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol 2012; 166 (6) : 1069-77.
42. Rosenfeld RG, Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract 2008; 14 (2) : 143-54.
43. Desrosiers P, O'Brien F, Blethen S. Patient outcomes in the GHMonitor: The effect of delivery device on compliance and growth. Pediatr Endocrinol Rev 2005; (2 Suppl. 3) : 327-31.
44. Kapoor RR, Burke SA, Sparrow SE, et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child 2008; 93 (2) : 147-8.
45. Cutfield WS, Derraik JG, Gunn AJ, et al. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One 2011; 6 (1) : 6223.
46. Silverman BL, Blethen SL, Reiter EO, et al. Along-acting human growth hormone (Nutropin Depot) : Efficacy and safety following two years of treatment in children with growth hormone deficiency. J Pediatr Endocrinol Metab 2002; 2: 715-22.
47. Hoffman AR, Biller BM, Cook D, et al. Genentech Adult Growth Hormone Deficiency Study, G. Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. J Clin Endocrinol Metab 2005; 90 (12) : 6431-40.
48. Biller BM, Ji HJ, Ahn H, et al. Effects of once-weekly sustained-release growth hormone: A double-blind, placebocontrolled study in adult growth hormone deficiency. J Clin Endocrinol Metab 2011; 96 (6) : 1718-26.
49. Peter F, Bidlingmaier M, Savoy C, et al. Three year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD) . J Clin Endocrinol Metab 2012; 97 (2) : 400-7.
50. Fares F, Guy R, Bar-Ilan A, et al. Designing a long-acting human growth hormone (hGH) by fusing the carboxylterminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of hGH. Endocrinology 2010; 151 (9) : 4410-7.
51. Sondergaard E, Klose M, Hansen M, et al. Pegylated long-acting human growth hormone possesses a promising onceweekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 2011; 96 (3) : 681-8.
52. Yuen KC, Conway GS, Popovic V, et al. A long-acting human growth hormone with delayed clearance (VRS-317) : Results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults. J Clin Endocrinol Metab 2013; 98: 2595-603.
53. Höybye C, Christiansen JS. Long-acting growth hormone. Peadiatr Drugs 2013; 15 (6) : 427-9.